NewsNovo
A law firm is questioning whether AtaiBeckley (Nasdaq: ATAI) is obtaining fair value for its public shareholders in a recently announced transaction with Eli Lilly.
Ademi LLP, based in Milwaukee, launched the investigation citing possible breaches of fiduciary duty and other violations of law. The firm has opened the inquiry to shareholders who want to participate.
What the probe targets The core of Ademi LLP's investigation is a pricing question.
The firm is examining whether AtaiBeckley's board met its legal obligation to seek the best available terms for public shareholders in the Eli Lilly deal.
Keep reading